AUA21 Day 1 eNews - 091021-v2

INSIDE FRIDAY. SEPTEMBER 10, 2021 AUA DAILY NEWS Welcome to AUA2021! T he AUA isn’t letting the pandemic get in the way of innovative, evidence- based, quality programming for urologists and urologic health care professionals worldwide. The AUA2021 virtual platform will offer access to all of the interactive and engaging science and education from the comfort of your home or office. “We look forward to offering you the same vibrant programming you have come to expect from the AUA and opportunities to reflect and connect over the emerging and leading topics within our specialty,” said AUA Secretary John D. Denstedt, MD, FRCSC, FACS, FCAHS. The AUA2021 Virtual Meeting kicks off today with hundreds of hours of live and on-demand content, including: • More than 400 CME credits available • Plenary Sessions — featuring today’s leaders in urology and popular sessions like Crossfire Debates, Surgical Techniques, Second Opinion Cases and more (translated into Spanish and Portuguese) • New Clinical Guidelines — sessions on the new 2021 clinical guidelines • Instructional Courses —more than 40 courses that span the spectrum of urology • Poster, Podium and Video Sessions — this year’s accepted abstracts presented virtually by the authors • Confederación Americana de Urología (CAU) program— Annual Meeting’s most popular Spanish-speaking program • Special programming like the Young Urologists and Residents Forums — addressing the topics impacting today’s residents and young urologists • Industry Programming — virtual presentations on the latest technologies and advances in industry The virtual meeting will include a robust offering of learning and engagement, including educational programming, abstracts, keynotes, surgical videos and space to connect with sponsors, exhibitors and educators from across the globe. In addition to participating in the live event, all attendees will have access to on-demand recording through the end of 2021. PEMBROLIZUMAB IMMUNOTHERAPY 3 ADVANCED PROSTATE CANCER 4 LOCALIZED RENAL MASSES 6 GRANT INVITES DIVERSITY 8 STONE DISEASE 12 Final results for sublingual UTI vaccine to be announced T he final results of a pivotal phase 3 trial of a polybacterial vaccine candidate for recurrent urinary tract infections (UTIs) in women will be revealed during the Late Breaking Abstracts session “A Novel Sublingual Vaccine Will Dramatically Alter the Clinical Management of Recurrent Urinary Tract Infections in Women” on Sunday. Uromune, developed and manufactured by Immunotek, has shown UTI-free rates of 33% to 78% at one year in early phase uncontrolled studies. “The results being presented at this session will represent the future of UTI management, not only in women with recurrent UTIs but for other urological infectious diseases,” said one of the principal investigators, J. Curtis Nickel, MD, FRCSC, professor of urology at Queen’s University and Tier 1 Canada research chair in urologic pain and inflammation at Kingston Health Sciences Centre in Canada. “This could be a game changer for urologists and their patients who suffer from UTIs.” Uromune is a sublingual spray, used by patients once daily for three months. Other oral and vaginal vaccines have been developed, Dr. Nickel noted, but trial results have not supported guideline recommendations to consider their use or product marketing approval in North America. Recurrent UTIs are a significant unmet need, Dr. Nickel said. Half of women will suffer from a UTI at some point during their lives, and up to 40% of these women will have recurrent UTIs with three or more infections per year. The Don’t Miss A Novel Sublingual Vaccine Will Dramatically Alter the Clinical Management of Recurrent Urinary Tract Infections in Women Sunday, September 12 9:10 – 9:20 a.m. PDT J. Curtis Nickel, MD, FRCSC see VACCINE page 12 The results being presented at this session will represent the future of UTI management, not only in women with recurrent UTIs but for other urological infectious diseases.” J. Curtis Nickel, MD, FRCSC Friday, September 10 7:30 – 8 a.m. PDT Panel Discussion: The Future of Urologic Oncology: How Will the Role of the Urologic Cancer Surgeon be Affected by Advances in Technology and Science? 8:45 – 9:05 a.m. PDT Point-Counterpoint Debate: Open Radical Prostatectomy is No Longer Relevant in Urologic Residency 9 – 11 a.m. PDT New Technology in the Management of Stone Disease: What’s New, What Works, & What to Buy 9:55 – 10:25 a.m. PDT Crossfire: Controversies in Urology Debate: Can Focal Therapy Replace Prostatectomy in a Man With a Localized, Clinically Significant Lesion and a Negative Standard Biopsy? 2 – 4 p.m. PDT AUA Guidelines: Evaluation and Management of Localized Renal Masses: A Case-Based Approach 3:55 – 4:05 p.m. PDT Pembrolizumab vs. Placebo as Post Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma: Randomized, Double-Blind, Phase 3 KEYNOTE-564 Study